{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:24:29Z","timestamp":1767860669566,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Janus-activated kinase-1 (<jats:italic>JAK1<\/jats:italic>) plays a crucial role in many aspects of cell proliferation, differentiation, apoptosis and immune regulation. However, correlations of <jats:italic>JAK1<\/jats:italic> with prognosis and immune infiltration in NSCLC have not been documented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed the relationship between <jats:italic>JAK1<\/jats:italic> expression and NSCLC prognosis and immune infiltration using multiple public databases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>JAK1<\/jats:italic> expression was significantly decreased in NSCLC compared with that in paired normal tissues. <jats:italic>JAK1<\/jats:italic> overexpression indicated a favourable prognosis in NSCLC. In subgroup analysis, high <jats:italic>JAK1<\/jats:italic> expression was associated with a preferable prognosis in lung adenocarcinoma (OS: HR, 0.74, 95% CI from 0.58 to 0.95, log-rank <jats:italic>P<\/jats:italic>\u2009=\u20090.017), not squamous cell carcinoma. In addition, data from Kaplan\u2013Meier plotter revealed that <jats:italic>JAK1<\/jats:italic> overexpression was associated with a preferable prognosis in male and stage N2 patients and patients without distant metastasis. Notably, increased levels of <jats:italic>JAK1<\/jats:italic> expression were associated with an undesirable prognosis in patients with stage 1 (OS: HR, 1.46, 95% CI from 1.06 to 2.00, <jats:italic>P<\/jats:italic>\u2009=\u20090.02) and without lymph node metastasis (PFS: HR, 2.18, 95% CI from 1.06 to 4.46, <jats:italic>P<\/jats:italic>\u2009=\u20090.029), which suggests that early-stage NSCLC patients with <jats:italic>JAK1<\/jats:italic> overexpression may have a bleak prognosis. Moreover, multiple immune infiltration cells, including NK cells, CD8\u2009+\u2009T and CD4\u2009+\u2009T cells, B cells, macrophages, neutrophils, and dendritic cells (DCs), in NSCLC were positively correlated with <jats:italic>JAK1<\/jats:italic> expression. Furthermore, diverse immune markers are associated with <jats:italic>JAK1<\/jats:italic> expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:italic>JAK1<\/jats:italic> overexpression exhibited superior prognosis and immune infiltration in NSCLC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-021-04379-y","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T14:18:00Z","timestamp":1632925080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC"],"prefix":"10.1186","volume":"22","author":[{"given":"Kaikai","family":"Shen","sequence":"first","affiliation":[]},{"given":"Yuqing","family":"Wei","sequence":"additional","affiliation":[]},{"given":"Tangfeng","family":"Lv","sequence":"additional","affiliation":[]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[]},{"given":"Xiaogan","family":"Jiang","sequence":"additional","affiliation":[]},{"given":"Zhiwei","family":"Lu","sequence":"additional","affiliation":[]},{"given":"Ping","family":"Zhan","sequence":"additional","affiliation":[]},{"given":"Xianghai","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Meng","family":"Fan","sequence":"additional","affiliation":[]},{"given":"Weihua","family":"Lu","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"10","key":"4379_CR1","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.jtho.2019.05.044","volume":"14","author":"CB William","year":"2019","unstructured":"William CB, Caroline C, Timothy RC, et al. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol. 2019;14(10):1732\u201342.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"4379_CR2","doi-asserted-by":"publisher","first-page":"6636","DOI":"10.21037\/jtd.2018.11.72","volume":"10","author":"K Shen","year":"2018","unstructured":"Shen K, Cui J, Wei Y, et al. Effectiveness and safety of PD-1\/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: a meta-analysis. J Thorac Dis. 2018;10(12):6636\u201352.","journal-title":"J Thorac Dis"},{"issue":"6","key":"4379_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4379_CR4","first-page":"883","volume":"24","author":"N Soukalas","year":"2019","unstructured":"Soukalas N, Kiakou M, Tsapakidis K, et al. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. J BUON. 2019;24(3):883\u20138.","journal-title":"J BUON"},{"issue":"3","key":"4379_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10620-020-06111-x","volume":"65","author":"MAW Khan","year":"2020","unstructured":"Khan MAW, Ologun G, Arora R, et al. Gut microbiome modulates response to cancer immunotherapy. Dig Dis Sci. 2020;65(3):885\u201396.","journal-title":"Dig Dis Sci"},{"key":"4379_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126\u201333.","journal-title":"Cancer Lett"},{"issue":"8","key":"4379_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4379_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","volume":"66","author":"X Li","year":"2017","unstructured":"Li X, Yao W, Yuan Y, et al. Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157\u201367.","journal-title":"Gut"},{"issue":"3","key":"4379_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316\u201331.","journal-title":"Cancer Discov"},{"issue":"23","key":"4379_CR10","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.18632\/aging.102514","volume":"11","author":"B Chen","year":"2019","unstructured":"Chen B, Lai J, Dai D, et al. JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer. Aging (Albany NY). 2019;11(23):11124\u201335.","journal-title":"Aging (Albany NY)"},{"key":"4379_CR11","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.3389\/fimmu.2018.03108","volume":"9","author":"A Witalisz-Siepracka","year":"2019","unstructured":"Witalisz-Siepracka A, Klein K, Prinz D, et al. Loss of JAK1 drives innate immune deficiency. Front Immunol. 2019;9:3108.","journal-title":"Front Immunol"},{"issue":"8","key":"4379_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.celrep.2018.10.063","volume":"25","author":"BL Wehde","year":"2018","unstructured":"Wehde BL, R\u00e4dler PD, Shrestha H, et al. Janus kinase 1 plays a critical role in mammary cancer progression. Cell Rep. 2018;25(8):2192-2207.e5.","journal-title":"Cell Rep"},{"key":"4379_CR13","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.2147\/CMAR.S201342","volume":"11","author":"W Chen","year":"2019","unstructured":"Chen W, Wu G, Zhu Y, et al. HOXA10 deteriorates gastric cancer through activating JAK1\/STAT3 signaling pathway. Cancer Manag Res. 2019;11:6625\u201335.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"4379_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Orpaczy","year":"2018","unstructured":"Orpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood. 2018;132(7):694\u2013706.","journal-title":"Blood"},{"issue":"12","key":"4379_CR15","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1002\/ijc.32624","volume":"145","author":"J Mohrherr","year":"2019","unstructured":"Mohrherr J, Haber M, Breitenecker K, et al. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression. Int J Cancer. 2019;145(12):3376\u201388.","journal-title":"Int J Cancer"},{"issue":"4","key":"4379_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s13258-019-00907-6","volume":"42","author":"N Zhang","year":"2020","unstructured":"Zhang N, Li F, Gao J, et al. Osteopontin accelerates the development and metastasis of bladder cancer via activating JAK1\/STAT1 pathway. Genes Genom. 2020;42(4):467\u201375.","journal-title":"Genes Genom"},{"issue":"12","key":"4379_CR17","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1158\/1535-7163.MCT-14-0077","volume":"13","author":"W Wen","year":"2014","unstructured":"Wen W, Liang W, Wu J, et al. Targeting JAK1\/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther. 2014;13(12):3037\u201348.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"4379_CR18","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"issue":"20","key":"4379_CR19","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200\u20132.","journal-title":"Bioinformatics"},{"issue":"W1","key":"4379_CR20","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4379_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10549-016-4013-7","volume":"160","author":"A L\u00e1nczky","year":"2016","unstructured":"L\u00e1nczky A, Nagy \u00c1, Bottai G, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160(3):439\u201346.","journal-title":"Breast Cancer Res Treat"},{"key":"4379_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1755-8794-2-18","volume":"2","author":"H Mizuno","year":"2009","unstructured":"Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genom. 2009;2:18.","journal-title":"BMC Med Genom"},{"key":"4379_CR23","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3389\/fimmu.2018.02654","volume":"9","author":"AE Oja","year":"2018","unstructured":"Oja AE, Piet B, van der Zwan D, et al. Functional heterogeneity of CD4+ tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLC. Front Immunol. 2018;9:2654.","journal-title":"Front Immunol"},{"issue":"17","key":"4379_CR24","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2217\/bmm-2019-0178","volume":"13","author":"CA Castaneda","year":"2019","unstructured":"Castaneda CA, Castillo M, Aliaga K, et al. Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. Biomark Med. 2019;13(17):1481\u201391.","journal-title":"Biomark Med"},{"key":"4379_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fimmu.2018.00094","volume":"9","author":"O Danziger","year":"2018","unstructured":"Danziger O, Pupko T, Bacharach E, Ehrlich M. Interleukin-6 and interferon-\u03b1 signaling via JAK1-STAT differentially regulate oncolytic versus cytoprotective antiviral states. Front Immunol. 2018;9:94.","journal-title":"Front Immunol"},{"issue":"4","key":"4379_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity. 2012;36(4):503\u201314.","journal-title":"Immunity"},{"issue":"1","key":"4379_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","volume":"7","author":"A Osipov","year":"2019","unstructured":"Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019;7(1):224.","journal-title":"J Immunother Cancer"},{"issue":"7528","key":"4379_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"7787","key":"4379_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465\u201370.","journal-title":"Nature"},{"issue":"1","key":"4379_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s40425-019-0589-x","volume":"7","author":"S Althammer","year":"2019","unstructured":"Althammer S, Tan TH, Spitzm\u00fcller A, et al. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. J Immunother Cancer. 2019;7(1):121.","journal-title":"J Immunother Cancer"},{"key":"4379_CR31","doi-asserted-by":"publisher","first-page":"106088","DOI":"10.1016\/j.intimp.2019.106088","volume":"79","author":"L Wang","year":"2020","unstructured":"Wang L, Ma Q, Yao R, et al. Current status and development of anti-PD-1\/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol. 2020;79:106088.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"4379_CR32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845\u201351.","journal-title":"Nat Med"},{"issue":"15","key":"4379_CR33","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","volume":"25","author":"I Datar","year":"2019","unstructured":"Datar I, Sanmamed MF, Wang J, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 2019;25(15):4663\u201373.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4379_CR34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201847955","volume":"49","author":"E Kaleviste","year":"2019","unstructured":"Kaleviste E, Saare M, Leahy TR, et al. Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined. Eur J Immunol. 2019;49(5):790\u2013800.","journal-title":"Eur J Immunol"},{"issue":"2","key":"4379_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"key":"4379_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.immunol.15.1.563","volume":"15","author":"EA Bach","year":"1997","unstructured":"Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997;15:563\u201391.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"4379_CR37","doi-asserted-by":"publisher","first-page":"e0176181","DOI":"10.1371\/journal.pone.0176181","volume":"12","author":"LA Albacker","year":"2017","unstructured":"Albacker LA, Wu J, Smith P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11):e0176181.","journal-title":"PLoS ONE"},{"key":"4379_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"issue":"3","key":"4379_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","volume":"93","author":"SJ Rodig","year":"1998","unstructured":"Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93(3):373\u201383.","journal-title":"Cell"},{"issue":"6","key":"4379_CR40","doi-asserted-by":"publisher","first-page":"e1438106","DOI":"10.1080\/2162402X.2018.1438106","volume":"7","author":"N Luo","year":"2018","unstructured":"Luo N, Formisano L, Gonzalez-Ericsson PI, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7(6):e1438106.","journal-title":"Oncoimmunology"},{"issue":"8","key":"4379_CR41","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon DY, Abril-Rodriguez G, Champhekar AS, et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 2020;10(8):1140\u201357.","journal-title":"Cancer Discov"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-021-04379-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T15:05:42Z","timestamp":1632927942000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-021-04379-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4379"],"URL":"https:\/\/doi.org\/10.1186\/s12859-021-04379-y","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"471"}}